In the 2016 World Health Organization (WHO) pathological classification of central nervous system tumors, isocitrate dehydrogenase (IDH) mutation and 1p/19q combined deletion were indicated as the two most critical molecular pathological biomarkers for glioma and have been widely used in clinical diagnosis and therapy (8). The gene discussed is IDH3A; the disease is central nervous system cancer.